Angiogenesis Inhibitors/therapeutic use; Biomarkers, Tumor/blood; Carcinoma, Non-Small-Cell Lung/blood; Lung Neoplasms/blood; Neovascularization, Pathologic/blood; Small Cell Lung Carcinoma/blood; Thalidomide/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carboplatin/administration & dosage; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/mortality; Clinical Trials, Phase III as Topic; Deoxycytidine/administration & dosage; Deoxycytidine/analogs & derivatives; Etoposide/administration & dosage; Female; Fibroblast Growth Factor 2/blood; Humans; Intercellular Adhesion Molecule-1/blood; Interleukin-8/blood; Lung Neoplasms/drug therapy; Lung Neoplasms/mortality; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neovascularization, Pathologic/drug therapy; Neovascularization, Pathologic/mortality; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma/drug therapy; Small Cell Lung Carcinoma/mortality; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A/blood; Gemcitabine